基于因子分析法的我国基本药物采购政策实施影响因素研究

发布时间：2018-03-03 03:04

本文选题：基本药物　切入点：采购政策　出处：《中国药房》2017年30期 　论文类型：期刊论文

【摘要】：目的:评价我国新一轮基本药物招标采购政策,为保障我国基本药物供应稳定和完善国家基本药物制度提供参考。方法:在理论分析的基础上设计问卷,选取上海和云南为样本地区,对两地药品生产企业、流通企业和基层医疗卫生机构等相关人员开展调查,了解其在基本药物供应体系中遇到的困难以及当地药品招标采购双方对生产企业投标情况的具体评价,从中得出我国基本药物采购政策实施中各影响因素的类别分布,运用因子分析法筛选关键影响因素。结果与结论:共发现4个公共因子对我国基本药物采购政策的实施有较大的影响,其影响程度由大到小依次为招标采购方案的合理性、药品生产的规范性、药品使用需求的稳定性和宏观政策的调控与保障。建议相关部门进一步完善药品招采制度,遴选出质量保证、生产规范、充分满足市场多样化需求的品种,同时为生产企业提供相对稳定的使用量信息,必要时可通过政策强制推行上海模式的"带量采购",以此保证药品供应链中各方的利益诉求得到公平对待。
[Abstract]:Objective: to evaluate a new round of bidding and purchasing policies for essential drugs in China, and to provide a reference for ensuring the stability of the supply of essential drugs and improving the national essential drug system. Methods: a questionnaire was designed on the basis of theoretical analysis. Shanghai and Yunnan are selected as sample areas to investigate the relevant personnel of drug manufacturing enterprises, circulation enterprises and primary medical and health institutions in the two places. To understand the difficulties encountered in the supply system of essential drugs and the concrete evaluation of the bidding situation of the manufacturing enterprises by the local drug bidding and purchasing parties, and to obtain the distribution of the categories of factors affecting the implementation of the basic drug procurement policy in China, Results and conclusion: it is found that four public factors have great influence on the implementation of the procurement policy of essential drugs in China, and the degree of influence from big to small is the rationality of the bidding procurement scheme. The standardization of drug production, the stability of drug use demand and the regulation and guarantee of macro policies. It is suggested that the relevant departments should further improve the drug recruitment system, select quality assurance, standardize production, and fully meet the diversified needs of the market. At the same time, it can provide relatively stable usage information for manufacturing enterprises and enforce the "belt purchase" of Shanghai model through policies when necessary, so as to ensure that the interests of all parties in the pharmaceutical supply chain are treated fairly.
【作者单位】：中国药科大学国际医药商学院;昆明医科大学药学院暨云南省天然药物药理重点实验室;
【基金】：国家社会科学基金资助项目(No.14BGL144)
【分类号】：R951

【相似文献】